RAPHAEL PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.75 USD | -54.27% |
|
-54.27% | -25.00% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 18.5M 25.26M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -4.1M | Net income 2023 | -1M -1.37M | EV / Sales 2022 * | - |
| Net cash position 2022 | 288K 393K | Net cash position 2023 | 230K 314K | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-13
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.54% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -54.27% | ||
| 1 week | -54.27% | ||
| Current month | -54.27% | ||
| 1 month | -51.30% | ||
| 3 months | -25.00% | ||
| 6 months | -25.00% | ||
| Current year | -25.00% |
1 week
0.75
1.31
1 month
0.751.64
Current year
0.751.64
1 year
0.601.67
3 years
0.602.50
5 years
0.602.50
10 years
0.602.50
Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company. The Company is focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol (CBD) oil. The Company is in pre-clinical development stage for its lead product candidate, rheumatoid arthritis (RA), for the treatment of RA. In addition, the Company is also developing a pharmaceutical drug product for the treatment of hyperinflammatory syndrome inflammation related to COVID-19. The Companyâs discovery platform focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient (API), for its RA product candidate and COVID-19 product candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| -25.00% | 14.03M | |
| +37.76% | 52.5B | |
| -7.47% | 39.01B | |
| +37.72% | 39.31B | |
| +11.93% | 26.2B | |
| -11.17% | 26.57B | |
| +16.45% | 28.2B | |
| +45.05% | 14.15B | |
| +33.13% | 12.62B | |
| -3.46% | 11.74B |
- Stock Market
- Equities
- RAPH Stock
